Skip to main content
Fig. 1 | The Journal of Headache and Pain

Fig. 1

From: CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs

Fig. 1

dropouts due to AEs and change in MMD versus placebo in episodic migraine patients. The size of the circle corresponds to the number of patients that were treated with the prophylactic agent across all RCTs. can: candesartan; ami: amitriptyline; top: topiramate: val: valproate; CGRP: CGRP mAb; β: beta-blockers; RCT: randomised controlled trial; MMD: monthly migraine days

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us